Eledon Pharmaceuticals Reports Positive Data in Type 1 Diabetes Study; Shares Rise

MT Newswires Live10-29

Eledon Pharmaceuticals (ELDN) reported positive initial data from a diabetes study after the first two of three islet transplant recipients achieved insulin independence at three months post-transplant.

The subjects were treated with an immunosuppression regimen that includes tegoprubart, Eledon's investigational anti-CD40L antibody, aimed at preventing islet transplant rejection in individuals with type 1 diabetes.

The trial showed the potential first human cases of the achievement of insulin independence using an anti-CD40L monoclonal antibody therapy without tacrolimus, the current standard of care to prevent transplant rejection, the company said Tuesday in a statement.

The third subject lowered insulin use by 60% three days after receiving an islet transplant and remains on track for insulin independence, the company said.

The company said treatment with tegoprubart was generally well-tolerated.

Eledon shares rose 11% in recent Tuesday trading.

Price: 3.75, Change: +0.38, Percent Change: +11.28

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment